CA ATC L01EB03 · updated 2 Nov 2026
Afatinib shortage in Canada
Is there an Afatinib shortage in Canada?
Yes. As of 2 Nov 2026, 9 Afatinib products are reported short in Canada, the first since 3 Aug 2026. The company estimate for the return is 4 Dec 2026 (latest 31 Jan 2027). Main reason: other.
Not reported short in any other country we track. All countries.
Affected products in Canada
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | SANDOZ AFATINIB (30FCT) | SANDOZ CANADA INCORPORATED | 3 Aug 2026 | 4 Dec 2026 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | SANDOZ AFATINIB (30 FCT) | SANDOZ CANADA INCORPORATED | 14 Sep 2026 | 4 Dec 2026 | Active ingredient shortage Shortage of an active ingredient |
| CA | SANDOZ AFATINIB (30FCT) | SANDOZ CANADA INCORPORATED | 14 Sep 2026 | 4 Dec 2026 | Active ingredient shortage Shortage of an active ingredient |
| CA | GIOTRIF (4x28) anticipated discontinuation | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 31 Jan 2027 | 31 Jan 2027 | Other Other (Please describe in comments) |
| CA | GIOTRIF (4x7) anticipated discontinuation | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 31 Jan 2027 | 31 Jan 2027 | Other Other (Please describe in comments) |
| CA | GIOTRIF (4x7) anticipated discontinuation | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 31 Jan 2027 | 31 Jan 2027 | Other Other (Please describe in comments) |
| CA | GIOTRIF (4x28) discontinuation | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | not given | 31 Jan 2027 | Not stated |
| CA | GIOTRIF (4x28) discontinuation | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | not given | 31 Jan 2027 | Not stated |
| CA | GIOTRIF (4x28) discontinuation | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | not given | 31 Jan 2027 | Not stated |
Source
Health Canada, Health Product Shortages Canada. Official list. Mandatory company reports since 2017: actual and anticipated shortages, plus products about to be discontinued.